WallStSmart

Galapagos NV ADR (GLPG)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 111% more annual revenue ($606.42M vs $286.92M). GLPG leads profitability with a -1.5% profit margin vs -2.1%. GLPG earns a higher WallStSmart Score of 47/100 (D+).

GLPG

Hold

47

out of 100

Grade: D+

Growth: 9.3Profit: 2.0Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GLPG3 strengths · Avg: 9.3/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

EPS GrowthGrowth
74.8%10/10

Earnings expanding 74.8% YoY

Revenue GrowthGrowth
18.9%8/10

18.9% revenue growth

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

GLPG4 concerns · Avg: 1.5/10
Return on EquityProfitability
-16.7%2/10

ROE of -16.7% — below average capital efficiency

Free Cash FlowQuality
$-43.28M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-1.5%1/10

Currently unprofitable

Operating MarginProfitability
-58.6%1/10

Operating margin of -58.6%

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GLPG

The strongest argument for GLPG centers on Price/Book, EPS Growth, Revenue Growth. Revenue growth of 18.9% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : GLPG

The primary concerns for GLPG are Return on Equity, Free Cash Flow, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

GLPG profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

GLPG is growing revenue faster at 18.9% — sustainability is the question.

GLPG generates stronger free cash flow (-43M), providing more financial flexibility.

Bottom Line

GLPG scores higher overall (47/100 vs 39/100) and 18.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Galapagos NV ADR

HEALTHCARE · BIOTECHNOLOGY · USA

Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?